Secukinumab 30 mg/kg IV and 10 mg/kg IV , compared with the 300 mg SC dose , produced higher responder rates ( 72.7 % and 61.5 % vs. 33.3 % , respectively ) and remission rates ( 27.3 % and 38.5 % vs. 16.7 % , respectively ) .